Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

By

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

ROR1 Expression May Enhance Disease Progression in CLL

ROR1 Expression May Enhance Disease Progression in CLL

By

Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

By

In an observational study of an independent cohort of patients with Binet stage A CLL, researchers sought to validate the ability of the CLL International Prognostic Index to predict time to first treatment (TTFT) and overall survival in patients with early-stage disease.

Chronic Lymphocytic Leukemia (Fact Sheet)

Chronic Lymphocytic Leukemia (Fact Sheet)

This fact sheet reviews the incidence and survival statistics of chronic lymphocytic leukemia.

Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain

Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain

[ClinicoEconomics and Outcomes Research] This research examines the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of previously untreated chronic lymphocytic leukemia.

MRD Assessment Improves PFS Prediction in Patients With CLL

MRD Assessment Improves PFS Prediction in Patients With CLL

By

Assessment of minimal residual disease (MRD) improves the prediction of progression-free survival benefit in patients with CLL who achieve either a complete response or a partial response PR.

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

By

The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

By

Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

By

Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Rituximab Maintenance Prolongs PFS in Patients With CLL

Rituximab Maintenance Prolongs PFS in Patients With CLL

By

New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

By

An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

By

The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.

Hair, Nail Abnormalities Common With Ibrutinib Therapy

Hair, Nail Abnormalities Common With Ibrutinib Therapy

By

Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.

Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and Metastasis

Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and Metastasis

By

Wnt5a protein acts on a pair of tumor-surface proteins to accelerate the proliferation and spread of CLL. These effects of Wnt5a were blocked by a humanized monoclonal antibody called cirmtuzumab, according to a recent study.

ASH: Ibrutinib Superior to Chlorambucil for Chronic Lymphocytic Leukemia

ASH: Ibrutinib Superior to Chlorambucil for Chronic Lymphocytic Leukemia

Improvements were observed in progression-free survival, overall survival, and response rate for ibrutinib usage.

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

By

For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

By

Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

By

The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.

Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL

Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL

By

ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.

Long-term remissions achieved in first personalized cell therapy trial

By

Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.

Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL

Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL

By

A new meta-analysis of 26 factors has resulted in an internationally applicable prognostic index for patients with chronic lymphocytic leukemia, according to study results presented at 2015 ASCO Annual Meeting.

Targeting CD20 in chronic lymphocytic leukemia

Targeting CD20 in chronic lymphocytic leukemia

[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.

FDA approves new sBLA for Gazyva plus chlorambucil

FDA approves new sBLA for Gazyva plus chlorambucil

Genentech announced that the FDA has approved the sBLA for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL).

Risk prediction improved by new classification in chronic lymphocytic leukemia

Risk prediction improved by new classification in chronic lymphocytic leukemia

By

A new correlation discovered between specific molecular disease features and subgroups of patients with different prognoses could make identification of chronic lymphocytic leukemia (CLL) prognosis at the time of diagnosis possible.

Resistance to ibrutinib in chronic lymphocytic leukemia explained

Resistance to ibrutinib in chronic lymphocytic leukemia explained

By

A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.

New drug for non-Hodgkin lymphoma and chronic leukemia succeeds in phase I

By

A new chemotherapy drug being investigated for its potency against two types of cancer was found to be effective in about one-third of the participants in a phase I study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs